Coloplast A/S (OTCMKTS:CLPBY) Stock Price Up 15.2% on Analyst Upgrade

Shares of Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY) shot up 15.2% during mid-day trading on Wednesday after Barclays upgraded the stock from a hold rating to a strong-buy rating. The stock traded as high as $7.84 and last traded at $7.7750. Approximately 42,445 shares changed hands during trading, a decline of 90% from the average session volume of 429,517 shares. The stock had previously closed at $6.75.

Coloplast A/S Stock Performance

The stock has a 50-day simple moving average of $6.85 and a 200-day simple moving average of $6.79. The company has a debt-to-equity ratio of 1.51, a current ratio of 1.56 and a quick ratio of 0.94. The stock has a market cap of $17.20 billion, a PE ratio of 36.33, a P/E/G ratio of 2.85 and a beta of 0.10.

Coloplast A/S (OTCMKTS:CLPBY) last released its quarterly earnings data on Tuesday, November 3rd. The company reported $0.09 EPS for the quarter, hitting analysts’ consensus estimates of $0.09. Coloplast A/S had a return on equity of 42.25% and a net margin of 10.57%. The company had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.12 billion. Equities analysts predict that Coloplast A/S Sponsored ADR will post 0.40 earnings per share for the current fiscal year.

About Coloplast A/S

Coloplast A/S is a Denmark-based medical technology company that develops, manufactures and markets products designed to help people manage intimate health conditions. Its core businesses include ostomy care, continence care, wound and skin care, and interventional urology. The company’s products are used by patients and healthcare professionals in hospitals, clinics and home-care settings.

Coloplast was founded in Denmark in 1957 after nurse Elise Sørensen helped develop an adhesive ostomy bag for her sister, who had undergone surgery.